We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Thrombosis Associated with Immunomodulatory Agents in Multiple Myeloma

Jose Ramon Gonzalez-Porras and María-Victoria Mateos

Hematology Department, Hospital Universitario de Salamanca and IBSAL, Salamanca Spain

1. Introduction

Patients with multiple myeloma (MM) are increasingly at risk for thromboembolic events (TEEs), usually venous thromboembolism (VTE) [1]. The introduction of thalidomide and lenalidomide has clearly improved outcomes in MM patients but these immunomodulatory agents (IMiDs) are also associated with higher rates of TEEs [2]. The pathogenesis of thalidomide/lenalidomide-associated thrombosis is multifactorial and poorly understood. Patients with MM who are being treated with schemes including combinations of either thalidomide or lenalidomide plus other agents should receive some form of thrombosis prophylaxis [3]. This chapter discusses the incidence, pathogenic mechanisms, prophylaxis and treatment of thalidomide/lenalidomide-associated TEEs.

2. Multiple myeloma and thrombosis

The risk of developing venous thrombotic complications for patients with cancer is approximately five times that of the general population (0.5 vs. 0.1%) [4]. Multiple myeloma (MM), characterized by the malignant proliferation of clonal plasma cells, accounts for approximately 10% of hematologic malignancies and affects older individuals (median age, 70 years) [5]. Thromboembolic events are a key concern in clonal plasma cells disorders, such as monoclonal gammopathy of undetermined significance (MGUS) as well as in MM. The exact incidence of VTE in MGUS is difficult to determine since reported VTE rates probably vary according to the level of diagnostic vigilance. The underlying medical problems that prompted laboratory testing for monoclonal may also increase the risk of VTE. Srkalovic et al [1] noted an increased incidence of VTE among patients with MGUS. They reported that 7.5% (13 of 174 patients) of patients with MGUS developed VTE at a median of 4 months (range, 0–67 months) after diagnosis. The cumulative VTE rate was 16% after 8 years of follow-up. A medical history of VTE, family history of VTE, immobility, low serum albumin level and an increase in leukocyte count were found to be correlated with increased incidence of VTE in patients with MGUS. In another retrospective study (310 patients with MGUS) the incidence of VTE was 6.1% after a median follow-up of 44 months [6]. Univariate analysis showed that age ≥ 65 years, M protein ≥ 16 g/l and disease progression to symptom MM were the significant risk factors for VTE. A retrospective review of U.S. Veterans Affairs hospital records from 1980–1996 reported an incidence of VTE of 0.9, 3.1 and 8.7% in veterans without a plasma cell dyscrasia, diagnosed to have

MGUS, and MM, respectively [7]. The incidence of VTE in MM patients is difficult to estimate and varies from 3–10%. On the other hand, the recent introduction of the anti-myeloma therapy class called immunomodulatory drugs (IMiDs), substantially increased risk of VTE in multiple myeloma.

The exact pathogenesis of thrombosis in plasma cell dyscrasia is multifactorial and poorly understood. Prothrombotic coagulation abnormalities are found in patients with newly diagnosed multiple myeloma, including elevated levels of von Willebrand antigen factor, factor VIII and tissue factor, as well as decreased protein S and thrombospondin [8]. Proinflammatory and angiogenic cytokines such as interleukin-6, tumor necrosis factor and vascular endothelial growth factor (VEGF) are elevated in MM and could activate the coagulation system [9]. A recently described mechanism of hypercoagulability in cancer patients, including MM patients, is acquired activated protein C resistance (APC-R). APC-R, in the absence of factor V Leiden mutation, was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of VTE [10]. The possible production of auto-antibodies against protein C in these patients could explain the transient APC resistance phenotype. However, to date, we know of no single prothrombotic abnormality that can be used to predict which patients with plasma cell dyscrasia will develop VTE. Other risk factors of MM-associated thrombosis are involved, such as older age, immobility, prior or family history of VTE and the presence of other medical comorbidities, immobility due to pain and/or surgery, indwelling central venous catheters, extrinsic venous compression by plasmacytomas, and the presence of inherited factors such as factor V Leiden. However, the dominant risk factor for VTE in MM is the type of drug administered.

3. Thalidomide and thrombosis

Thalidomide is a glutamic acid derivative that exerts potent anti-angiogenic and immunomodulatory activity and has revolutionized clinical management of patients with myeloma. Thalidomide is effective in relapsed or refractory and newly diagnosed MM. However, from experience with myeloma patients, VTE has recently emerged as the single most important complication. The anti-myeloma effect is mediated by several mechanisms in myeloma cells directly as well as by the microenvironment [11]. Thalidomide induces G1 growth arrest/apoptosis by inhibiting NF- κ B [12] and activating caspase. It inhibits adhesion of myeloma cells to bone marrow stromal cells, and inhibits secretion of cytokines (VEGF, [13], β FGF, [14–16], HGF, [17], TNF α , [18], IL-6, [19] and soluble IL-6 receptor (sIL-6R) [20]); up-regulate ICAM-1, [21] VCAM-1, IL-10, [22–23] and IL-12, [24]. Finally, it induces T cell and NK cell anti-myeloma immunity and inhibits angiogenesis [25].

The occurrence of VTE with the use of thalidomide was reported for the first time by Osman and Rajkumar in two independent phase 2 trials [31] in 2001. The combination of thalidomide (100–200 mg/day), doxorubicin (36 mg/m² on the first day of each 28-day cycle,) and dexamethasone (40 mg daily on days 1–4, 9–12, and 17–20 of each cycle) produced symptomatic deep venous thrombosis in four of the first 15 enrolled patients (27%) and the trial was therefore stopped. The other phase 2 trial combined thalidomide and dexamethasone for the treatment of patients with newly diagnosed myeloma at the Mayo Clinic. Seven percent (3/45) had thrombotic events. Cavo [32] and Rajkumar [33] in another

two phase 3 trials confirmed the preliminary observations of increased incidence of VTE in newly diagnosed MM treated with thalidomide plus dexamethasone (16 and 17% of VTEs). (table 1 below).

Regimen	n	Status of disease	Incidence (%)
Thalidomide in monotherapy			
Barlogie, 2001 ²⁶	169	RR	< 2
Bennet, 2001 ²⁷	326	RR	4.6
Rajkumar, 2002 ²⁸	31	RR	3.4
Tosi, 2002 ²⁹	65	RR	1.5
Weber, 2002 ³⁰	28	ND	3
Thalidomide / Dexamethasone			
Cavo, 2004 ³²	71	ND	16
Rakjumar, 2006 ³³	103	ND	17
Palumbo, 2004 ³⁴	120	RR	2
Dimopoulos, 2001 ³⁵	44	RR	7
Thalidomide / Melphalan / Prednisone			
Palumbo, 2006 ³⁶	129	ND	20
Facon, 2007 ³⁷	125	ND	12
Thalidomide / Melphalan / Dexamethasone			
Dimopoulos 2006 ³⁸	50	ND	9
Thalidomide / Dexamethasone / CTX			
Sidra, 2006 ³⁹	62	ND / RR	3.2
García-Sanz, 2004 ⁴⁰	71	RR	7
Dimopoulos, 2004 ⁴¹	53	RR	4
Kropff, 2003 ⁴²	60	RR	9
Moehler, 2003 ⁴³	56	RR	7
Thalidomide / Chemotherapy			
Baz, 2005 ⁴⁴	35	ND/RR	58
Zangari, 2004 ³	87	ND	34
Zangari, 2002 ⁴⁵	232	RR	16
Barlogie, 2006 ⁴⁶	323	ND	34
Schutt, 2005 ⁴⁷	31	ND	26
Zervas, 2004 ⁴⁸	39	ND	10

RR: refractory / relapsed; ND: newly diagnosed.

Table 1. Incidence of thalidomide-associated venous thromboembolism without VTE prophylaxis

Similarly, when thalidomide was combined with melphalan and steroids, the incidence of VTE was 9–20% in newly diagnosed elderly patients [36–38]. In all of these studies, the major risk of thrombosis occurs early after initiation of the treatment, when the tumor load is maximal. Thus, this complication may be related to the release of thrombogenic factors from myeloma cells rather than to cumulative drug exposure [49].

A meta-analysis of studies of thalidomide in MM, which involved 3,322 patients, showed that patients receiving thalidomide were 2.1 times as likely to have a VTE event compared with those who were not receiving thalidomide ($p < 0.01$). Those receiving thalidomide plus dexamethasone were 3.1 times as likely to have a VTE event ($p < 0.01$), and those receiving thalidomide in addition to other chemotherapy agents were 1.5 times as likely to have a VTE event ($p < 0.01$) [2].

The pathogenesis of thalidomide-associated thrombosis has not yet been established. Zangari et al. [10] tested for hypercoagulability in 62 newly diagnosed MMs, and found that DVT was more frequent in those patients with acquired APC resistance (36 vs. 15%, $p < 0.04$). The pre-existing elevated factor VIII coagulant activity and von Willebrand factor antigen have also been related with thalidomide-associated thrombosis [50]. In an experimental model, Kausahal et al. demonstrated that the addition of thalidomide to uninjured arterial endothelium did not cause any appreciable change, whereas thalidomide added to adriamycin-injured (8–24 h) endothelial cells resulted in endothelial dysfunction by altering the expression of PAR-1 in injured endothelium [51].

Cases of VTE that began shortly after the initiation of treatment with recombinant human erythropoietin in patients who had been receiving thalidomide for some time have been reported [52]. However, another study found no apparent increased risk of thrombosis in 199 cases of myeloma given thalidomide with or without erythropoietin. Of the 49 patients receiving both drugs, 8.1% developed thrombosis compared with 9.3% of the 150 patients on thalidomide who did not receive erythropoietin [53].

The genetic susceptibility to developing a VTE in response to thalidomide therapy has been also evaluated. The lack of a strong association with genetic variations in the coagulation cascade, such as factor V Leiden or G20210A prothrombin mutation, suggests that VTE risk is mediated via alternative mechanisms. Johnson et al [54] identified 18 SNPs, using a custom-built molecular inversion probe (MIP)-based single nucleotide polymorphism (SNP) chip. There were two “response to stress” groups: a response to DNA damage group, including *CHEK1*, *XRCC5*, *LIG1*, *ERCC6*, *DCLRE1B* and *PARP1*, and a cytokine response group containing *NFKB1*, *TNFRSF17*, *IL12B* and *LEP*. A third apoptosis-related group with *CASP3*, *PPARD* and *NFKB1* was also found.

Interestingly, no thromboembolic events were observed in a group of 30 patients with relapsed MM treated with a bortezomib, melphalan, prednisone and thalidomide (VMPT) combination despite the absence of any anticoagulant prophylaxis [55]. A recent review of phase 3 trials of bortezomib- and/or IMiD-based therapy in frontline MM, together with other studies of novel combination regimens concluded that bortezomib-based regimens were typically associated with DVT/PE rates of $\leq 5\%$, similar to those seen with melphalan-prednisone and dexamethasone, whereas IMiD-based bortezomib-free regimens were generally associated with higher rates [56]. These results suggested the existence of a protective effect of coadministration of thalidomide or lenalidomide with bortezomib [57–58]. Zangari et al prospectively described *in vivo* effects of bortezomib from routine tests of blood coagulation and platelet function in treated MM patients. This pilot clinical trial showed *in vivo* that even a short exposure to bortezomib can affect platelet function. Platelet aggregation was reduced after bortezomib infusion with most of the commonly agonists used (ADP, epinephrine and ristocetin) on both days of treatment [59].

The majority of thrombotic events described in patients receiving treatment with thalidomide have been venous, but occasional arterial thrombotic events have also been reported [60-63]. In a prospective analysis of arterial thrombosis risk, the incidence of arterial thrombosis in patients with newly diagnosed MM treated with three cycles of thalidomide, doxorubicin and dexamethasone (TAD group) was 4.5%. However, the true incidence of arterial thrombosis could have been underestimated in the TAD group due to prophylactic use of LMWH. High factor VIII:C levels, possibly reflecting disease activity, could contribute to the risk of arterial thrombosis especially in patients with known cardiovascular risk factors [64].

4. Lenalidomide and thrombosis

Lenalidomide, a more potent immunomodulatory derivative of thalidomide, was designed to increase the anti-myeloma efficacy of thalidomide, while possibly reducing side effects like neuropathy and thrombosis. However, although neuropathy is not an important lenalidomide-related side effect, thrombosis continues to be one of the most important side effects, especially when lenalidomide is given in combination with dexamethasone or chemotherapy (table 2).

Regimen	n	Status of disease	Incidence (%)
Lenalidomide in monotherapy			
Richardson, 2009 ⁶⁵	222	RR	4
Lenalidomide / Dexamethasone			
Dimopoulos, 2007 ⁶⁶	176	RR	11.4
Weber, 2007 ⁶⁷	177	RR	14.7
Zonder, 2005 ⁶⁸	38	ND	75
Rajkumar 2010 ⁶⁹	223	ND	26
Lenalidomide / Dexamethasone Low Dose			
Rajkumar, 2010 ⁶⁹	222	ND	12
Lenalidomide / Dexamethasone / Bortezomib			
Richardson, 2010 ⁷⁰	66	ND	6

RR: refractory / relapsed; ND: newly diagnosed.

Table 2. Incidence of lenalidomide-associated venous thromboembolism without VTE prophylaxis

In two large phase 3 trials comparing lenalidomide plus dexamethasone to dexamethasone alone without mandated thromboprophylaxis in patients with RRMM, the incidences of VTE in the LD arm were 11.4 and 14.7%, compared with 4.6 and 3.4% in the DEX alone arm [66-67]. The incidence was even higher in patients with newly diagnosed MM (up to 75%) who were treated with lenalidomide plus dexamethasone [68]. In all these trials conducted in RR and newly diagnosed MM patients, dexamethasone was given at high dose (three pulses of 40 mg for 4 days, total amount per cycle: 480 mg). Interestingly, the rate of VTE was significantly lower when lenalidomide was combined

with low-dose dexamethasone (40 mg weekly; total dose per cycle: 160mg) compared with high-dose (26 *vs.* 12%, $p=0.0003$) [69].

Similar to thalidomide, low rates of VTE have been reported in MM patients treated with lenalidomide in combination with bortezomib. In a phase 1/2 study of lenalidomide plus dexamethasone and bortezomib without thromboprophylaxis, thrombosis was rare (6% overall) [70].

The role of ESA and lenalidomide in thrombotic risk is controversial. An increased thrombotic risk has been observed in patients who received concomitant ESA with lenalidomide plus dexamethasone [71], although a third study showed no impact of ESA [72].

5. Pomalidomide and thrombosis

Pomalidomide (CC4047) is a new IMiD with high *in vitro* potency. In a phase 1 trial evaluating CC-4047 alone in 24 patients with RRMM, 4 (17%) developed a TEE during the first year of therapy [73]. Thromboprophylaxis was given in the phase 2 studies of pomalidomide and low-dose dexamethasone [74-78].

6. Prophylaxis of TEE-related IMiDs

Patients with MM being treated with IMiDs-based combinations should receive thromboprophylaxis [79-80]. There are data showing benefit of using low-molecular-weight heparin (LMWH), full-dose warfarin and daily aspirin in myeloma patients receiving IMiDs drugs [3, 44, 81]. However, fixed-dose warfarin (1 mg/d) was ineffective in reducing the VTE rate [3, 36]. Currently, outpatient VTE prophylaxis is recommended by the Italian Association of Medical Oncology, the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the French National Federation of the League of Centers Against Cancer and the European Society of Medical Oncology only for medical oncology patients receiving highly thrombogenic thalidomide- or lenalidomide-based combination chemotherapy regimens [80].

The 2008 International Myeloma Working Group consensus statement on VTE prophylaxis in myeloma patients receiving thalidomide or lenalidomide [81], recommends a prophylaxis strategy according to a risk-assessment model. Individual risk factors for VTE associated with thalidomide and lenalidomide therapy include: advanced age, a history of VTE, an indwelling central venous catheter, comorbid conditions (e.g, infections, diabetes, cardiac disease, etc), current or recent immobilization, recent surgery and inherited thrombophilic abnormalities. Myeloma-related risk factors include diagnosis and hyperviscosity. Therapy-related risk factors include high-dose dexamethasone, doxorubicin or multiagent chemotherapy in combination with thalidomide or lenalidomide, but not with bortezomib. The panel recommends aspirin for patients with ≤ 1 risk factor for VTE. LMWH (equivalent to enoxaparin 40 mg per day) is recommended for those with two or more individual/myeloma-related risk factors. LMWH is also recommended for all patients receiving concurrent high-dose dexamethasone or doxorubicin. Full-dose warfarin targeting a therapeutic INR of 2-3 is an alternative to LMWH, although little has been published about this strategy (see figure 1 below).

Fig. 1. International Myeloma Working Group consensus statement on VTE prophylaxis in myeloma patients receiving thalidomide or lenalidomide (2008).

Two direct comparison trials between thromboprophylaxis agents have recently been conducted. In the first phase 3 Italian Myeloma Network GIMEMA study [82], which prospectively assessed the impact of LMWH, aspirin or low-dose warfarin in newly diagnosed patients receiving thalidomide as part of either VMPT, VTD or TD regimens, the risk of VTE was similar in all three thromboprophylactic therapies after 6 months of follow up (5.0, 6.4 and 8.2%, respectively), and all were considered likely to be effective.

The second phase 3 trial compared the efficacy and safety of thromboprophylaxis with low-dose aspirin (ASA) or low-molecular-weight heparin (LMWH) in newly diagnosed MM patients, treated with lenalidomide and low-dose dexamethasone induction and melphalan-prednisone lenalidomide consolidation. The incidence of VTE was 2.27% in the ASA group and 1.20% in the LMWH group. The authors concluded that aspirin could be an effective and less expensive alternative to LMWH thromboprophylaxis during treatment with lenalidomide [83].

However, some questions remain unanswered: the outcome of the use of thromboprophylaxis in patients already in remission receiving thalidomide or lenalidomide as maintenance therapy during prolong periods of time is not well understood. A recent meta-analysis of the use of thalidomide as maintenance after autologous transplantation found the incidence of thromboembolic events to be 4-6%, and the risk of thromboembolism

was 1.95 times that of patients who did not receive thalidomide [84]. The use of ASA for a longer period may reduce the risk of late thromboembolism. Future studies should address this possibility.

7. Management of IMiD-associated VTE

No studies or guidelines are available to guide treatment of established thalidomide/lenalidomide-associated VTE. Although the use of LMWH has improved VTE management in patients with solid tumors [85], no similar experience has been built up in patients with MM. The recommended treatment for thalidomide- or lenalidomide-associated thrombosis is either LMWH or warfarin. However, the use of LMWH is more attractive because of the lack of need for laboratory monitoring and the reduced variability (compared with warfarin) caused by interference from drugs and food. Also, in patients with solid tumors, LMWH administered for 6 months after a first VTE episode (1 month at full dose and 5 months at approximately 75% of the full dose) has proved to be safe and superior to warfarin in preventing VTE recurrence [85]. However, the optimal duration of anticoagulation therapy in oncology patients remains controversial.

The optimal doses of the most commonly used LMWH are 100 U/kg every 12 h or 200 U/kg daily for dalteparin, 1 mg/kg every 12 h or 1.5 mg/kg daily for enoxaparin, and 86 U/kg every 12 h or 171 U/kg daily for nadroparin. In patients with a high risk of hemorrhage (thrombocytopenia or renal failure), association of monitoring of peak anti-factor Xa levels to maintain a range of 0.5 to 1.0 IU/mL could be very attractive. In addition, a reduction of 50% of the therapeutic dose of LMWH for platelet counts less than $50 \times 10^9/\mu\text{L}$, and a temporary discontinuation of LMWH for platelet counts less than $20,000 \times 10^9/\mu\text{L}$ can be performed [86]. Also, UFH followed by warfarin remains a sensible alternative for VTE treatment in patients with $\text{CrCl} < 30 \text{ ml/min}$ [87].

Zangari et al reported the treatment of 14 patients who developed thalidomide-related VTE. In 75% of them, administration of thalidomide was safely resumed after appropriate anticoagulation therapy was initiated. This consisted of low-molecular-weight heparin followed by warfarin, the target being the international normalized ratio of 2.5 to 3. Both anticoagulant and thalidomide treatments were continued as long as they were clinically indicated [88].

Alternative anti-myeloma treatment with an IMiS-free scheme should be seriously considered in patients who develop a VTE receiving LMWH or warfarin therapy with an appropriate INR [89]. However, if the use of IMiDs which produced the VTE is absolutely necessary, an alternative anticoagulant scheme could be used. In this setting, in patients with cancer-associated thrombosis while on warfarin therapy, with an appropriate INR, a recommended practice is to switch them to LMWH because it is more efficacious than warfarin [90]. On the other hand, dose escalation appears to be effective in patients who develop a cancer-associated thrombosis while on LMWH. In a small cohort study of oncology patients with recurrent thrombosis while on LMWH or warfarin, escalating the dose of LMWH by 20–25% or switching to LMWH, respectively, prevented further thrombotic episodes [91].

8. References

- [1] Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. *Cancer*. 2004;101: 558-566.
- [2] El Accaoui RN, Shamseddeen WA, Taher AT: Thalidomide and thrombosis: A meta-analysis. *Thromb Haemost*. 2007;97: 1031-1036.
- [3] Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. *Br J Haematol*. 2004;126: 715-721.
- [4] Lee AY, Levine MN: Venous thromboembolism and cancer: Risks and outcomes. *Circulation*. 2003;107: I17-I21.
- [5] Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review 1975-2007. based on November 2009 SEER data submission, posted to the SEER website. http://seer.cancer.gov/csr/1975_2007/. Accessed 12 January 2011.
- [6] Sallah S, Husain A, Wan J, et al. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. *Ann Oncol*. 2004; 15: 1490-1494.
- [7] Kristinsson S, Fears T, Gridley G, et al. Deep vein thrombosis following monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. *Blood*. 2008;112: 3582-3586.
- [8] Auwerda JJA, Sonneveld P, de Maat MPM, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. *Haematologica* 2007; 92: 279-280.
- [9] Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. *Thromb Haemost*. 2005;94: 362-365.
- [10] Zangari M, Saghaifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. *Blood Coagul Fibrinolysis*. 2002;13: 187-192.
- [11] Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. *Blood*. 2000;96: 2943-2950.
- [12] Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibitor of NFκB activity by thalidomide through suppression of IκB kinase activity. *J Biol Chem*. 2001;276: 22382-22387.
- [13] Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. *Blood*. 2000;95: 2630-2636
- [14] Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. *Eur J Cancer*. 2006;42:1581-1590.
- [15] Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. *Eur J Haematol*. 2001;66: 83-88.
- [16] Urbanska-Rys H, Wierzbowska A, Robak T. Circulating angiogenic cytokines in multiple myeloma and related disorders. *Eur Cytokine Netw*. 2003;14: 40-51.

- [17] Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. *Blood*. 2007;109: 3024-3030.
- [18] Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. *Oncogene*. 2001;20: 4519-4527.
- [19] Klein B, Zhang XG, Lu ZY, et al. Bataille R. Interleukin- 6 in human multiple myeloma. *Blood*. 1995; 85: 863-872.
- [20] Dmoszynska A, Podhorecka M, Manko J, et al. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. *Neoplasma*. 2005;52: 175-181.
- [21] Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. *Immunopharmacology*. 1996;31: 213-221.
- [22] Gu ZJ, Costes V, Lu ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. *Blood*. 1996;88: 3972-3986.
- [23] Lu ZY, Zhang XG, Rodriguez C, et al. Interleukin- 10 is a proliferation factor but not a differentiation factor for human myeloma cells. *Blood*. 1995;85: 2521-2527.
- [24] Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. *Clin Exp Immunol*. 2001;125: 190-197.
- [25] D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci USA*. 1994;91: 4082- 4085.
- [26] Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. *Blood*. 2001;98: 492-494.
- [27] Bennett CL, Schumok GT, Kwaan HC, et al. High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered (abstract). *Blood*. 2001;98: 863a.
- [28] Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. *J Clin Oncol*. 2002;20: 4319-4323.
- [29] Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. *Haematologica*. 2002;87: 408-414.
- [30] Weber D, Ginsberg C, Walker P, et al. Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD) (abstract). *Blood*. 2002;100: 787.
- [31] Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. *N Engl J Med*. 2001;344: 1951-1952.
- [32] Cavo M, Zamagni E, Tosi P, et al: First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. *Haematologica*. 2004;89: 826-831.
- [33] Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol*. 2006;24: 431-436.

- [34] Palumbo A, Bertola A, Falco P, et al: Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. *Hematol J*. 2004;5: 318-324.
- [35] Dimopoulos MA, Zervas K, Kouvatses G, et al: Thalidomide and dexamethasone combination for refractory multiple myeloma. *Ann Oncol*. 2001;12: 991- 995.
- [36] Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. *Lancet*. 2006;367: 825-831
- [37] Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. *Lancet*. 2007;370: 1209-1218
- [38] Dimopoulos MA, Anagnostopoulos A, Terpos E, et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. *Haematologica*. 2006;91: 252-254.
- [39] Sidra G, Williams CD, Russell NH, et al. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. *Haematologica*. 2006;91: 862-863.
- [40] Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/ refractory multiple myeloma. *Leukemia* 2004;18: 856-863.
- [41] Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. *Hematol J*. 2004;5: 112-117.
- [42] Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. *Br J Haematol*. 2003;122: 607-616.
- [43] Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. *Blood*. 2001;98: 3846-3848.
- [44] Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. *Mayo Clin Proc*. 2005;80: 1568-1574.
- [45] Zangari M, Siegel E, Barlogie B, et al: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. *Blood*. 2002;100: 1168-1171.
- [46] Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med*. 2006;354: 1021-1030.
- [47] Schutt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. *Eur J Haematol*. 2005;74: 40-46.
- [48] Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. *Ann Oncol*. 2004;15: 134-138.
- [49] Anderson KC. Advances in disease biology: therapeutic implications. *Semin Hematol*. 2001;38(Suppl 3): 6-10.

- [50] Ward CM, Yen T, Harvie R, et al. Elevated levels of factor VIII and von Willebrand factor after thalidomide treatment for malignancy: Relationship to thromboembolic events (abstract). *Hematol J*. 2003;4(suppl 1): 365.
- [51] Kaushal V, Kaushal GP, Melkaveri SN, et al. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. *J Thromb Haemost*. 2004;2: 327-334.
- [52] Steurer, M, Sudmeier, I, Stauder, R, et al. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-a. *Br J Haematol*. 2003;121: 101-103.
- [53] Galli M, Elice F, Crippa C, et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. *Haematologica*. 2004;89: 1141-1142.
- [54] Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. *Blood*. 2008;112: 4924-4934.
- [55] Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. The Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologiche dell'Adulto. *Blood*. 2007;109: 2767-2772.
- [56] Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. *Clin Lymphoma Myeloma Leuk*. 2011;11:228- 236.
- [57] Ostrowska JD, Wojtukiewicz MZ, Chabielska E, et al. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. *Thromb Haemost* 2004;92: 171-177.
- [58] Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. *Hematology*. 2007;12: 235-239.
- [59] Zangari M, Guerrero J, Cavallo F, et al. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. *Haematologica*. 2008;93: 953-954.
- [60] Goz M, Eren MN, Cakir O. Arterial trombosis and thalidomide. *J Thromb Thrombolysis*. 2008;25: 224-226.
- [61] Altintas A, Ayyildiz O, Atay AE, et al. Thalidomide-associated arterial thrombosis: two case reports. *Ann Acad Med Singapore*. 2007;36: 304-306.
- [62] Alkindi S, Dennison D, Pathare A. Arterial and venous thrombotic complications with thalidomide in multiple myeloma. *Arch Med Res*. 2008;39(2): 257-258.
- [63] Raven W, Berghout A, van Houten A, et al. Treatment of multiple myeloma and arterial thrombosis. *Ann Hematol*. 2010;89(4):419-420.
- [64] Libourel EJ, Sonneveld P, van der Holt B, et al. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. *Blood*. 2010;116: 22-26.
- [65] Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. *Blood*. 2009;114: 772-778.

- [66] Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. *N Engl J Med*. 2007;357: 2123-2132.
- [67] Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. *N Engl J Med*. 2007; 357:2133-2142.
- [68] Zonder JA, Durie BGM, McCoy J, et al. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis (abstract). *Blood*. 2005;106:3455a.
- [69] Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. *Lancet Oncol*. 2010;11: 29-37.
- [70] Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood*. 2010;116: 679-686.
- [71] Niesvizky,R., Spencer,A., Wang,M. (2006) Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin (abstract). *J Clin Oncol*. 2006;24, 7506a.
- [72] Menon SP, Rajkumar SV, Lacy M, et al. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. *Cancer*. 2008;112: 1522-1528.
- [73] Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. *J Clin Oncol*. 2004;22: 3269-3276.
- [74] Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. *J Clin Oncol* 2009;27: 5008-5014.
- [75] Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). *Leukemia*. 2010;24: 1934-1939.
- [76] Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. *Blood*. 2011;118: 2970-2975.
- [77] Leleu X, Attal M, Moreau P, et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma (abstract). *Blood*. 2010;116: 859a.
- [78] Richardson PG, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib (abstract). *Blood*. 2010;116: 864a.
- [79] Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma *Leukemia*. 2008;22: 414-423.

- [80] Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. *J Clin Oncol*. 2009;27: 4919-4926.
- [81] Palumbo A, Rus C, Zeldis JB, et al: Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. *J Thromb Haemost*. 2006;4: 1842-1845.
- [82] Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. *J Clin Oncol*. 2011;29: 986-993.
- [83] Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. *Blood*. 2011[Epub ahead of print].
- [84] Hicks LK, Haynes AE, Reece DE, et al: A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. *Cancer Treat Rev*. 2008;34: 442-452.
- [85] Lee AY, Levine MN, Baker RI, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med*. 2003;349:146-153.
- [86] Rickles FR, Falanga A, Montesinos P, et al. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? *Thromb Res*. 2007;120 Suppl 2: S99-106.
- [87] Clark NP. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. *Thromb Res*. 2008;123 Suppl 1: S58-61.
- [88] Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. *Blood* 2001;98: 1614-1615.
- [89] Zonder JA. Thrombotic Complications of Myeloma Therapy. *Hematology Am Soc Hematol Educ Program*. 2006;2010: 348-55.
- [90] Lee AYY. Thrombosis in cancer: An update on prevention, treatment, and survival benefits of anticoagulants. *Hematology Am Soc Hematol Educ Program*. 2010;2010: 144-149.
- [91] Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. *J Thromb Haemost*. 2009;7:760 – 765.

**Pathophysiology and Clinical Aspects of Venous
Thromboembolism in Neonates, Renal Disease and Cancer
Patients**

Edited by Dr. Mohamed A. Abdelaal

ISBN 978-953-51-0616-6

Hard cover, 166 pages

Publisher InTech

Published online 16, May, 2012

Published in print edition May, 2012

Venous Thromboembolism remains a major health challenge in many countries because of the morbidity and mortality it inflicts, mainly in hospitalized patients. This book, with contributions from distinguished experts in the field, depicts some hot aspects on aetiologies of VTE, the disease burden in neonates, renal disease and cancer patients as well as issues relevant to prophylaxis and the concept of VTE as patient injury content.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Jose Ramon Gonzalez-Porras and Maria-Victoria Mateos (2012). Thrombosis Associated with Immunomodulatory Agents in Multiple Myeloma, Pathophysiology and Clinical Aspects of Venous Thromboembolism in Neonates, Renal Disease and Cancer Patients, Dr. Mohamed A. Abdelaal (Ed.), ISBN: 978-953-51-0616-6, InTech, Available from: <http://www.intechopen.com/books/pathophysiology-and-clinical-aspects-of-venous-thromboembolism-in-neonates-renal-disease-and-cancer-patients/thrombosis-associated-with-immunomodulatory-agents-in-multiple-myeloma>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen